Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00254761 · ClinicalTrials.gov registry record · Phase 1

Effects of Smoked Marijuana on Neuropathic Pain

A Phase 1 study of Neuropathic Pain, sponsored by Center for Medicinal Cannabis Research.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT00254761: Completed Phase 1 study of Neuropathic Pain, sponsored by Center for Medicinal Cannabis Research.

NCT00254761 is a Phase 1 study of Neuropathic Pain that has completed, run by Center for Medicinal Cannabis Research. The registered enrollment target is 28 participants, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00254761, a Phase 1 study of Neuropathic Pain, has completed, sponsored by Center for Medicinal Cannabis Research.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

To determine if smoking marijuana will reduce neuropathic pain without causing too much drowsiness or feeling "too dopey".

Conditions Studied

Interventions

  • DRUG Cannabis

Study Locations (1)

California

  • UC Davis Medical Center - Sacramento

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2003-11
Est. Completion 2006-02
Phase Phase 1

What the finished NCT00254761 record still lists

NCT00254761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which Cannabis is the first listed.

NCT00254761 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00254761 about?

NCT00254761 is a clinical study titled "Effects of Smoked Marijuana on Neuropathic Pain". To determine if smoking marijuana will reduce neuropathic pain without causing too much drowsiness or feeling "too dopey".

What is the current status of trial NCT00254761?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2003-11. Estimated completion is 2006-02.

What conditions does trial NCT00254761 study?

This clinical trial studies the following conditions: Neuropathic Pain.

What interventions are being tested in trial NCT00254761?

The interventions under investigation include: Cannabis (DRUG).

Who is sponsoring clinical trial NCT00254761?

This trial is sponsored by Center for Medicinal Cannabis Research, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00254761 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00254761's enrollment target sits among peer trials

28 24th of 35 higher than 12 of 35 other Neuropathic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00254761, the US trial registry maintained by the National Library of Medicine. NCT00254761 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.